Oral Iron Supplementation for Patients With Chronic Kidney Disease

Status Active, not recruiting

Clinical Trial Summary

The hypothesis of this research is that oral iron prescribed in a single dose in alternate day could mitigate the side effects with regard to intestinal microbiota, inflammation, oxidative stress and improve the hematological profile when compared to daily oral iron prescription

Clinical Trial Description

chronic kidney disease triggers several changes in the body, anemia is one of the first disorders that appear in chronic kidney disease patients. The anemia in this patient is multifactorial, the main cause being relative erythropoietin deficiency, although iron deficiency is also common. In this context, the need for oral iron supplementation is a way of both treating iron deficiency and optimizing the use of agents that stimulate erythropoiesis. However, this replacement can cause iron overload, increasing the production of reactive oxygen species and, consequently, oxidative stress, and also alter the intestinal microbiota leading to poor iron absorption, worsening the prognosis of chronic kidney disease. The current routine for iron supplementation for these patients is to offer oral iron daily, which can be more harmful than when given on alternate days. However, there are few studies comparing the two prescriptions. In this context, since no study to date has been carried out to show the aforementioned effects in the participant with chronic kidney disease, this randomized clinical trial aims to assess the effects of daily or alternate-day oral iron supplementation on gut microbiota composition in participants with chronic kidney disease (glomerular filtration rate (GFR) below 30 mL/min) for 3 months. The project will also compare the effects of both prescriptions on serum hepcidin levels, markers of oxidative stress and inflammation, and on routine hematological and biochemical parameters. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05544513
Study type	Interventional
Source	Universidade Federal Fluminense
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	August 1, 2022
Completion date	December 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05632497` - Alteration of Symbiosis Intestinal Microbiota on Patients With Anorexia Nervosa
Recruiting	`NCT05560087` - Association of PeRiODontal Disease and gUt Microbiome With Coronary artEry Disease (PRODUCE Study)
Recruiting	`NCT05288790` - Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT	Phase 2
Completed	`NCT05575050` - Impact of Teeth Brushing in Ventilated COVID-19 Patients.	N/A
Completed	`NCT04079218` - Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial	Phase 4
Active, not recruiting	`NCT03554278` - Alteration of Stool Microbiota in Preterm Infants With Anemia
Completed	`NCT03659240` - Prebiotic Effects of a Polyphenol-rich Food Product	N/A
Completed	`NCT04118049` - Vaginal Probiotics and Pessaries and Their Impact on the Vaginal Microenvironment	N/A
Enrolling by invitation	`NCT06122636` - Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC	N/A
Recruiting	`NCT04200521` - The Effect of Bariatric Procedures on Gut Microbiota in Obese Individuals in United Arab Emirates and Lebanon
Completed	`NCT03523403` - Obesity-related Health Benefits of Apples	N/A
Recruiting	`NCT05176535` - Determination of Vaginal Colonization and the Effect of an Oral Probiotic (PROSALVAG)	N/A
Recruiting	`NCT06005298` - Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention	N/A
Completed	`NCT03675048` - Lactobacillus Reuteri DSM 17938 in Gut Microbiota Development in Infant Born by Caesarean Section	N/A
Completed	`NCT03043300` - A Pilot Study Assessing Intestinal Microbiota Diversification and Changes After Travel to South(East) Asia From the US
Recruiting	`NCT05790564` - Almonds to Improve Gut Health and Decrease Inflammation	N/A
Completed	`NCT04561284` - Carbohydrate-induced Resilience of the Gut Microbiome After Antibiotics Use	N/A
Enrolling by invitation	`NCT04527055` - The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication	Phase 4
Recruiting	`NCT05622721` - REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
Recruiting	`NCT04790825` - Periodontal Therapy on the Gut Microbiome of Inflammatory Bowel Disease	N/A